Print pageEmail pageRSS Feeds

News releases

<< Back
ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2013 ASCO Annual Meeting

Company to Host Investor Meeting and Webcast with Scott Gettinger, M.D. on Monday, June 3 at 7:30 a.m. (CT)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 15, 2013-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical data on Iclusig® (ponatinib) and AP26113, its investigational inhibitor of anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR) and c-ros oncogene (ROS1), will be presented at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago, May 31 to June 4, 2013.

The schedule and meeting location for the sessions, together with the abstract information, and details on the Company’s investor briefing are listed below:

Ponatinib

   
 
Title: Phase II Study of Combination of HyperCVAD with Ponatinib in Frontline Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
Abstract No: 7024
Presenter: Elias Jabbour, M.D., (MD Anderson Cancer Center)
Poster: Displayed from 8:00 a.m. to 12:00 p.m. in S 405
Poster Discussion: Leukemia, Myelodysplasia, and Transplantation
Date & Time: Saturday, June 1, 2013, 12:00 p.m. (CT)
Location: S 406
 
Title: Use of Ponatinib to Inhibit Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors (GIST)
Abstract No: 10509
Presenter: Michael C. Heinrich, M.D. (Oregon Health & Science University)
Poster: Displayed from 8:00 a.m. to 12:00 p.m. in S 102
Poster Discussion: Sarcoma
Date & Time: Saturday, June 1, 2013, 12:00 p.m. (CT)
Location: S 100a
 
Title: Analysis of the Cardiovascular Risk Profile of Ph+ Leukemia Patients Treated with Ponatinib
Abstract No: 7048
Presenter: Hanna J. Khoury, M.D. (Winship Cancer Institute, Emory University)
Poster: Displayed from 8:00 a.m. to 12:00 p.m. in S 405
Poster Discussion: Leukemia, Myelodysplasia, and Transplantation
Date & Time: Saturday, June 1, 2013, 12:00 p.m. (CT)
Location: S 406
 
Title: Safety and Durability of Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Long-term Follow-Up of an Ongoing Phase 1 Study
Abstract No: 7063
Presenter: Michael J. Mauro, M.D. (Knight Cancer Institute, Oregon Health & Science University)
Poster Session: Leukemia, Myelodysplasia, and Transplantation
Date & Time: Sunday, June 2, 2013, 8:00 a.m. to 11:45 a.m. (CT)
Location: S Hall A2
 
Title: Treatment Response Monitoring in Chronic Phase CML (CP-CML) Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy in US Oncology Network
Abstract No: 7065
Presenter: Kathryn S. Kolibaba, M.D. (Compass Oncology, McKesson/US Oncology)
Poster Session: Leukemia, Myelodysplasia, and Transplantation
Date & Time: Sunday, June 2, 2013, 8:00 a.m. to 11:45 a.m. (CT)
Location: S Hall A2
 
Title: EPIC: A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Abstract No: TPS7129
Presenter: Jeffrey H. Lipton, M.D., Ph.D. (Ontario Cancer Institute, Princess Margaret Hospital)
Poster Session: Leukemia, Myelodysplasia, and Transplantation
Date & Time: Sunday, June 2, 2013, 8:00 a.m. (CT)
Location: S Hall A2
 
Title: Impact of Baseline Mutations on Response to Ponatinib and End of Treatment Mutation Analysis in Patients with Chronic Myeloid Leukemia
Abstract No: 7001
Presenter: Michael Deininger, M.D., Ph.D. (Huntsman Cancer Institute, University of Utah)
Oral Session: Leukemia, Myelodysplasia, and Transplantation
Date & Time: Tuesday, June 4, 2013, 8:00 a.m. (CT)
Location: E 354b
 
 

AP26113

 
Title: First-in-Human Dose-Finding Study of the ALK/EGFR Inhibitor AP26113 in Patients with Advanced Malignancies: Updated Results
Abstract No: 8031
Presenter: D.R. Camidge, M.D., Ph.D. (University of Colorado Cancer Center)
Poster: Displayed from 8:00 a.m. to 12:00 p.m. in E Hall D2
Poster Discussion: Lung Cancer – Non-small cell metastatic
Date & Time: Sunday, June 2, 2013, 11:30 a.m. (CT)
Location: E 450b
 

Investor and Analyst Briefing and Webcast

A breakfast meeting to review the most recent clinical data from the Phase 1 portion of an ongoing Phase 1/2 clinical trial of AP26113 with research analysts and institutional investors will feature Scott Gettinger, M.D., Associate Professor of Medicine at Yale University School of Medicine and members from ARIAD’s management. This meeting will be webcast live along with slides and can be accessed by visiting the investor relations section of the Company’s website at http://investor.ariad.com.

Date:     Monday, June 3, 2013
Time: 7:30 a.m. to 8:30 a.m. (CT)
Location: Chicago Hilton, Conference Room PDR2 on third floor
 

Space is limited. To request attendance at the meeting, please RSVP to Investor.RSVP@ariad.com by Wednesday, May 29, 2013.

A replay of the investor event will be available on the ARIAD website approximately three hours after the presentation and will be archived on the site for four weeks. To ensure a timely connection to the live webcast, participants should log onto the webcast at least 15 minutes prior to the scheduled start time.

About Iclusig® (ponatinib) tablets

Iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Iclusig.

Important Safety Information for Iclusig® (ponatinib)

WARNING: ARTERIAL THROMBOSIS and HEPATOTOXICITY

Arterial Thrombosis: Cardiovascular, cerebrovascular, and peripheral vascular thrombosis, including fatal myocardial infarction and stroke have occurred in Iclusig-treated patients. In clinical trials, serious arterial thrombosis occurred in eight percent of Iclusig-treated patients. Interrupt and consider discontinuation of Iclusig in patients who develop arterial thrombotic events.

Hepatotoxicity: Hepatotoxicity, liver failure and death have occurred in Iclusig-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue Iclusig for hepatotoxicity.

Please visit www.iclusig.com for full prescribing information, including boxed warning.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

Source: ARIAD Pharmaceuticals, Inc.

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-620-4888
Liza.heapes@ariad.com

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue